Cancer Therapy by Cyclin-Dependent Kinase Inhibitors (Cdkis): Bench to Bedside Publisher



Hassanzadeh A¹ ; Shomali N^{2, 3} ; Kamrani A^{2, 3} ; Soltanizangbar MS^{2, 3} ; Nasiri H³ ; Akbari M^{3, 4} Show Affiliations
Source: EXCLI Journal Published:2024

Abstract

A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, signi ficant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors. © 2024, Leibniz Research Centre for Working Environment and Human Factors. All rights reserved.